Scholarlink

Background <p>To evaluate structural and functional outcomes in patients with acute Vogt-Koyanagi-Harada (VKH) disease, based on the timing of systemic corticosteroid (CS) initiation and the early introduction of noncorticosteroid immunomodulatory therapy (IMT).</p> Methods <p>This retrospective single-centre study included 35 consecutive patients (70 eyes) diagnosed with acute Vogt-Koyanagi-Harada disease at a tertiary center in São Paulo, Brazil. Patients received methylprednisolone pulse therapy (1,000&#xa0;mg/day, 3 days) followed by gradually tapered oral prednisone (1&#xa0;mg/kg/day). Patients were classified by the timing of CS initiation. The early treatment group (ETG, <i>n</i> = 24) initiated CS within 30 days of onset and comprised two subgroups: CS monotherapy (Group 1, <i>n</i> = 9) and CS plus IMT within 3 months (Group 2, <i>n</i> = 15). Those treated after 30 days because of late presentation formed the late treatment group (LTG, Group 3, <i>n</i> = 11). Follow-up was 24 months with multimodal imaging and full-field electroretinography.</p> Results <p>At 24 months, 98.6% of the eyes achieved BCVA ≤ 0.3 logMAR (Snellen 20/40), with no significant differences among the groups. Compared with Groups 1 and 3, Group 2 achieved a prednisone dose of ≤ 10&#xa0;mg sooner (7.3 ± 1.8 months; <i>p</i> = 0.043) and had a significantly lower cumulative dose (8,719 ± 3,067 mg; <i>p</i> = 0.02). BCVA worsening episodes occurred less frequently in Group 2 than in Group 3 (6.7% vs. 59.1%; <i>p</i> &lt; 0.001). Compared with the ETG, the LTG presented higher rates of BCVA worsening episodes (59.1% vs. 16.7%; <i>p</i> = 0.004), anterior uveitis recurrences (45.5% vs. 8.3%; <i>p</i> = 0.02), subretinal fibrosis (45.5% vs. 8.3%; <i>p</i> = 0.02), and peripapillary atrophy (72.7% vs. 22.9%; <i>p</i> = 0.003). Adverse events occurred in 7 patients (20%): 6 related to azathioprine and 1 related to CS therapy.</p> Conclusions <p>Early initiation of high-dose CS in VKH disease patients was associated with fewer relapses and structural complications. Early IMT introduction provided a CS-sparing effect, although it did not significantly improve visual or structural outcomes. Prompt CS initiation remains critical; further studies should identify patients who may benefit most from early IMT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of early treatment in acute Vogt-Koyanagi-Harada disease: a 24-month retrospective analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Marcelo Mendes Lavezzo,
  • Camillo Carneiro Gusmão,
  • Viviane Mayumi Sakata,
  • Fernanda Maria S. Souto,
  • Ruy Felippe B. G. Missaka,
  • Priscilla Figueiredo C. da Nóbrega,
  • Emmett T. Cunninghan Jr,
  • Maria Kiyoko Oyamada,
  • Carlos Eduardo Hirata,
  • Joyce Hisae Yamamoto

摘要

Background

To evaluate structural and functional outcomes in patients with acute Vogt-Koyanagi-Harada (VKH) disease, based on the timing of systemic corticosteroid (CS) initiation and the early introduction of noncorticosteroid immunomodulatory therapy (IMT).

Methods

This retrospective single-centre study included 35 consecutive patients (70 eyes) diagnosed with acute Vogt-Koyanagi-Harada disease at a tertiary center in São Paulo, Brazil. Patients received methylprednisolone pulse therapy (1,000 mg/day, 3 days) followed by gradually tapered oral prednisone (1 mg/kg/day). Patients were classified by the timing of CS initiation. The early treatment group (ETG, n = 24) initiated CS within 30 days of onset and comprised two subgroups: CS monotherapy (Group 1, n = 9) and CS plus IMT within 3 months (Group 2, n = 15). Those treated after 30 days because of late presentation formed the late treatment group (LTG, Group 3, n = 11). Follow-up was 24 months with multimodal imaging and full-field electroretinography.

Results

At 24 months, 98.6% of the eyes achieved BCVA ≤ 0.3 logMAR (Snellen 20/40), with no significant differences among the groups. Compared with Groups 1 and 3, Group 2 achieved a prednisone dose of ≤ 10 mg sooner (7.3 ± 1.8 months; p = 0.043) and had a significantly lower cumulative dose (8,719 ± 3,067 mg; p = 0.02). BCVA worsening episodes occurred less frequently in Group 2 than in Group 3 (6.7% vs. 59.1%; p < 0.001). Compared with the ETG, the LTG presented higher rates of BCVA worsening episodes (59.1% vs. 16.7%; p = 0.004), anterior uveitis recurrences (45.5% vs. 8.3%; p = 0.02), subretinal fibrosis (45.5% vs. 8.3%; p = 0.02), and peripapillary atrophy (72.7% vs. 22.9%; p = 0.003). Adverse events occurred in 7 patients (20%): 6 related to azathioprine and 1 related to CS therapy.

Conclusions

Early initiation of high-dose CS in VKH disease patients was associated with fewer relapses and structural complications. Early IMT introduction provided a CS-sparing effect, although it did not significantly improve visual or structural outcomes. Prompt CS initiation remains critical; further studies should identify patients who may benefit most from early IMT.